Cingulate Inc (CING)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Shane J. Schaffer
Employees:
1901 W. 47TH PLACE, KANSAS CITY, KS 66205
(913) 942-2300

We are a clinical stage biopharmaceutical company using our proprietary Precision Timed Release, or PTR, drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Our primary executive offices are located at 1901 West 47th Place, Kansas City, Kansas.

Data derived from most recent annual or quarterly report
Market Cap 16.286 Million Shares Outstanding11.309 Million Avg 30-day Volume 56.947 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0021 EBITDA-23.724 Million
Price to Book Value1.3909 Operating Margin0.0 Enterprise Value9.698 Million
Current Ratio8.936 EPS Growth0 Quick Ratio7.735
1 Yr BETA 1.4957 52-week High/Low 5.15 / 1.04 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score-2.2901 Free Cash Flow to Firm 0
Earnings Report2022-08-11

View recent insider trading info

Funds Holding CING (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CING BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

400 total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MYERS LAURIE EVP AND COO

  • Officer
46,716 2022-06-01 5

WERTH PETER J.

  • Director
893,580 2022-03-17 4

CALLAHAN JENNIFER L. CORPORATE CONTROLLER

  • Officer
36,943 2022-03-16 4

SCHAFFER SHANE J. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
66,500 2022-03-15 4

GIVENS GREGG WM

  • Director
89,318 2022-03-14 4

VAN HORN LOUIS G EVP AND CFO

  • Officer
156,606 2022-03-14 3

MEDEIROS CURTIS

  • Director
17,532 2022-03-14 3

GILGALLON CRAIG S. EVP & GENERAL COUNSEL

  • Officer
196,287 2022-03-14 3

GALLAGHER PATRICK JOSEPH

  • Director
9,000 2022-02-25 2

CONROY JEFFREY X

  • Director
9,000 2022-02-25 2

HARGROVES THOMAS JEFFREY

  • Director
9,000 2022-02-25 3

SILVA RAUL R. EVP AND CHIEF SCIENCE OFFICER

  • Officer
6,000 2022-02-25 2

BRAMS MATTHEW EVP AND CHIEF MEDICAL OFFICER

  • Officer
12,500 2022-02-25 2

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MYERS LAURIE - Officer EVP AND COO

2022-06-03 18:00:14 -0400 2022-06-01 P 200 $1.18 a 46,716 direct -0.7874 1.5748 10.2362 5 -0.7874 2

MYERS LAURIE - Officer EVP AND COO

2022-05-19 18:00:13 -0400 2022-05-17 P 200 $1.21 a 46,516 direct 1.6807 -5.042 1.6807 2 -7.563 4

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CINGULATE INC CING 2022-06-30 22:15:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 21:45:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 21:15:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 20:45:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 20:15:04 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 19:45:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 19:15:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 18:45:04 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 18:15:04 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 17:45:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 17:15:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 16:45:04 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 16:15:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 15:45:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 15:15:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 14:45:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 14:15:03 UTC -5.0401 6.6101 85000
CINGULATE INC CING 2022-06-30 13:45:03 UTC -4.9737 6.5437 85000
CINGULATE INC CING 2022-06-30 13:15:03 UTC -4.9737 6.5437 85000
CINGULATE INC CING 2022-06-30 12:45:03 UTC -4.9737 6.5437 85000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments